BRPI0518007A - formulação terapêutica capaz de produzir uma resposta imune contra a interleucina-2 e uso da mesma - Google Patents

formulação terapêutica capaz de produzir uma resposta imune contra a interleucina-2 e uso da mesma

Info

Publication number
BRPI0518007A
BRPI0518007A BRPI0518007-4A BRPI0518007A BRPI0518007A BR PI0518007 A BRPI0518007 A BR PI0518007A BR PI0518007 A BRPI0518007 A BR PI0518007A BR PI0518007 A BRPI0518007 A BR PI0518007A
Authority
BR
Brazil
Prior art keywords
immune response
relates
present
response against
therapeutic
Prior art date
Application number
BRPI0518007-4A
Other languages
English (en)
Inventor
Casimiro Jose Enrique Monteiro
Livan Bladimir Alonso Sarduy
Rodriguez Rolando Perez
Davila Agustin Bienvenido Lage
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of BRPI0518007A publication Critical patent/BRPI0518007A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMULAçãO TERAPêUTICA CAPAZ DE PRODUZIR UMA RESPOSTA IMUNE CONTRA A INTERLEUCINA-2 E USO DA MESMA. A presente invenção se relaciona com formulações farmacêuticas úteis no câncer mediante o bloqueio da união da interleucina 2 (IL-2) a seu receptor. Mais particularmente a presente invenção se relaciona com formulações terapêuticas capazes de incrementar a imunogenicidade e da IL-2 por seu acoplamento à proteína transportadora P64k da Neisseria Meningitidis em adjuvante Montanide ISA 51 para a indução de autoanticorpos bloqueadores da IL-2 a seu receptor e métodos efetivos para o tratamento de tumores, incluindo o câncer de mama. Em outro aspecto a presente invenção se refere à combinação terapêutica da vacina baseada em IL-2 com outras vacinas de câncer baseadas em antígenos específicos de tumores ou fatores de crescimento tumoral, assim como medicamentos quimioterapêuticos ou radioterapia de uso convencional na prática oncológica.
BRPI0518007-4A 2004-11-16 2005-11-16 formulação terapêutica capaz de produzir uma resposta imune contra a interleucina-2 e uso da mesma BRPI0518007A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20040261A CU23297A1 (es) 2004-11-16 2004-11-16 Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
PCT/CU2005/000009 WO2006053508A1 (es) 2004-11-16 2005-11-16 Formulaciones inmunoterapeuticas con capacidad neutralizante de la interleucina-2.

Publications (1)

Publication Number Publication Date
BRPI0518007A true BRPI0518007A (pt) 2008-10-21

Family

ID=40122436

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518007-4A BRPI0518007A (pt) 2004-11-16 2005-11-16 formulação terapêutica capaz de produzir uma resposta imune contra a interleucina-2 e uso da mesma

Country Status (24)

Country Link
US (1) US20090274647A1 (pt)
EP (2) EP1829893B1 (pt)
JP (1) JP5227028B2 (pt)
KR (1) KR101240457B1 (pt)
CN (1) CN101061136B (pt)
AR (1) AR051494A1 (pt)
AT (1) ATE525393T1 (pt)
AU (1) AU2005306186B2 (pt)
BR (1) BRPI0518007A (pt)
CA (1) CA2588573C (pt)
CR (1) CR9097A (pt)
CU (1) CU23297A1 (pt)
EA (1) EA012072B1 (pt)
GE (1) GEP20105039B (pt)
MA (1) MA29044B1 (pt)
MX (1) MX2007005808A (pt)
MY (1) MY162106A (pt)
PE (1) PE20061172A1 (pt)
SG (1) SG122897A1 (pt)
TN (1) TNSN07187A1 (pt)
TR (1) TR200704213T2 (pt)
TW (1) TWI433853B (pt)
WO (1) WO2006053508A1 (pt)
ZA (1) ZA200703528B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007271398B2 (en) * 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
WO2015162124A1 (en) * 2014-04-22 2015-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnostic of an autoimmune disease
CN115636880A (zh) 2015-10-23 2023-01-24 辉瑞有限公司 抗il-2抗体及其组合物和用途
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
CU24734B1 (es) * 2021-03-30 2025-02-07 Ct Inmunologia Molecular Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939832A (ja) * 1982-08-28 1984-03-05 Ajinomoto Co Inc モノクロ−ナル抗体ならびにその製法、使用法
EP0111344A2 (en) * 1982-12-13 1984-06-20 Sloan-Kettering Institute For Cancer Research Anti-interleukin-2 monoclonal antibodies
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
KR920703114A (ko) * 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
CU22302A1 (es) 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
US20040156824A1 (en) * 1996-12-23 2004-08-12 Epstein Alan L. Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
CA2219961C (en) * 1998-01-09 2010-06-01 The University Of Southern California Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US6168785B1 (en) * 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
EP1156823B1 (en) * 1999-02-12 2008-10-29 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
WO2001080889A1 (en) * 2000-04-26 2001-11-01 National Jewish Medical And Research Center Product and process for regulation of t cell responses
CU23011A1 (es) * 2000-11-03 2004-12-17 Ct Ingenieria Genetica Biotech Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
CU22999A1 (es) * 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
WO2002087304A2 (de) * 2001-04-30 2002-11-07 Frohnhofen, Wilfried Il2-peptide; von interleukin 2 abgeleitete peptide und peptid-dimere
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
DE60235041D1 (de) * 2001-11-30 2010-02-25 Us Gov Health & Human Serv Und ihre verwendung
ITMI20012527A1 (it) 2001-11-30 2003-05-30 Unihart Corp Proteine di fusione contenenti peptidi tlp
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
US7569215B2 (en) * 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides

Also Published As

Publication number Publication date
KR20070084025A (ko) 2007-08-24
KR101240457B1 (ko) 2013-03-08
JP2008526686A (ja) 2008-07-24
AR051494A1 (es) 2007-01-17
SG122897A1 (en) 2006-06-29
EP2112160A2 (en) 2009-10-28
HK1113374A1 (en) 2008-10-03
CR9097A (es) 2007-08-28
CU23297A1 (es) 2008-07-24
EP1829893B1 (en) 2011-09-21
CA2588573C (en) 2013-12-31
TWI433853B (zh) 2014-04-11
EA200701071A1 (ru) 2007-12-28
CN101061136B (zh) 2012-12-05
TNSN07187A1 (en) 2008-11-21
AU2005306186A1 (en) 2006-05-26
AU2005306186B2 (en) 2012-05-31
TR200704213T2 (tr) 2007-08-21
EP1829893A1 (en) 2007-09-05
EA012072B1 (ru) 2009-08-28
MX2007005808A (es) 2007-07-20
EP2112160A3 (en) 2010-01-13
GEP20105039B (en) 2010-07-12
WO2006053508A1 (es) 2006-05-26
TW200631591A (en) 2006-09-16
CA2588573A1 (en) 2006-05-26
EP2112160B1 (en) 2015-07-08
MY162106A (en) 2017-05-31
CN101061136A (zh) 2007-10-24
MA29044B1 (fr) 2007-11-01
ATE525393T1 (de) 2011-10-15
PE20061172A1 (es) 2006-12-16
JP5227028B2 (ja) 2013-07-03
US20090274647A1 (en) 2009-11-05
ZA200703528B (en) 2008-06-25

Similar Documents

Publication Publication Date Title
US12263210B2 (en) Immunogenic compounds for cancer therapy
Li et al. TLR agonists as adjuvants for cancer vaccines
Apostolopoulos et al. Dendritic cell immunotherapy: clinical outcomes
NZ591882A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
BR122019014468B8 (pt) uso de peptídeos de mhc de classe ii derivados de survivina
O'Mahony et al. Non–small-cell lung cancer vaccine therapy: a concise review
US12059460B2 (en) Immunogenic compounds for cancer therapy
Fournier et al. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008
US20160228524A1 (en) Autologous cancer cell vaccine
BRPI0518007A (pt) formulação terapêutica capaz de produzir uma resposta imune contra a interleucina-2 e uso da mesma
BR112014001363A2 (pt) peptídeos mphosph1 e vacinas incluindo os mesmos
Powell et al. BLP-25 liposomal vaccine: a promising potential therapy in nonsmall-cell lung cancer
Weiss et al. Update on vaccines for high-risk melanoma
MD3236985T2 (ro) Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva carcinomului hepatocelular (HCC) și altor cancere
BRPI0806257A2 (pt) método de tratamento, e, uso de uma composição imunoterapêutica
Talebi et al. Immuno-stimulating peptide derived from HMGB1 is more effective than the N-terminal domain of Gp96 as an endogenous adjuvant for improvement of protein vaccines
UY29216A1 (es) Formulaciones inmunoterapeúticas para la inducción de autoanticuerpos bloqueadores de la unión de interleucina-2 a su receptor. su uso en el tratamiento del cáncer
Kim et al. Unmet need in lung cancer: can vaccines bridge the gap?
DE60325586D1 (de) Mycobakterielle Proteinantigene für Krebstherapie und Impfung
CA2861565C (en) Autologous cancer cell vaccine
TH83896A (th) สูตรในการสร้างภูมิคุ้มกันเพื่อก่อให้เกิดออโตแอนติบอดีที่สามารถหลีกเลี่ยงการเชื่อมต่อของอินเตอร์ลิวคิน-2 เข้ากับตัวรับของตัวเอง การใช้สูตรในการบำบัดรักษาโรคมะเร็ง
TH83896B (th) สูตรในการสร้างภูมิคุ้มกันเพื่อก่อให้เกิดออโตแอนติบอดีที่สามารถหลีกเลี่ยงการเชื่อมต่อของอินเตอร์ลิวคิน-2เข้ากับตัวรับของตัวเอง การใช้สูตรในการบำบัดรักษาโรคมะเร็ง
Yücel Immunological Approach to Lung Cancer Part B: Immunological Therapies for Lung Cancer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.